Adynxx (ADYX) S-1 17 Jun 19 2019 Q1 IPO registration Financial data

Document And Entity Information

Document And Entity Information	3 Months Ended
	Mar. 31, 2019
Document Information [Line Items]
Entity Registrant Name	Adynxx, Inc.
Entity Central Index Key	0001054274
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Document Type	S-1
Document Period End Date	May 3, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Amendment Flag	false

Balance Sheets

Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 1,581	$ 1,887	$ 4,301
Restricted cash	255	55
Prepaid expenses and other current assets	396	10	34
Total current assets	2,232	1,952	4,335
Property and equipment, net	8	10	13
Right of use asset, net	165
Restricted cash			55
Other assets	18	18	18
Total assets	2,423	1,980	4,421
Current liabilities
Accounts payable	1,201	491	703
Accrued liabilities	1,193	857	1,158
Operating lease liability	173
Convertible promissory notes - related party	6,000	4,500
Current portion of term loan, net of discount	3,820	3,812	1,711
Total current Liabilities	12,387	9,660	3,572
Term loan, net of current portion and discount			2,951
Warrant liability	234	140	42
Commitments and contingencies (Note 6)
Stockholders' deficit:
Common stock, $0.001 par value;148,000,000 shares authorized; 19,548,969 shares issued and outstanding as of December 31, 2017, December 31, 2018 and March 31, 2019 (unaudited)	20	20	20
Additional paid-in capital	812	728	419
Accumulated deficit	(39,741)	(37,279)	(31,294)
Total stockholders' deficit	(38,909)	(36,531)	(30,855)
Total liabilities, redeemable convertible preferred stock and stockholders' deficit	2,423	1,980	4,421
Series A Redeemable Convertible Preferred Stock [Member]
Redeemable convertible preferred stock:
Redeemable convertible preferred stock	12,814	12,814	12,814
Series B Redeemable Convertible Preferred Stock [Member]
Redeemable convertible preferred stock:
Redeemable convertible preferred stock	$ 15,897	$ 15,897	$ 15,897

Balance Sheets (Parentheticals)

Balance Sheets (Parentheticals) - USD ($)	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	148,000,000	148,000,000	148,000,000
Common stock, shares issued (in shares)	19,548,969	19,548,969	19,548,969
Common stock, shares outstanding (in shares)	19,548,969	19,548,969	19,548,969
Series A Redeemable Convertible Preferred Stock [Member]
Redeemable convertible preferred stock, par value	$ 1	$ 1	$ 1
Redeemable convertible preferred stock, shares authorized (in shares)	57,002,183	57,002,183	57,002,183
Redeemable convertible preferred stock, shares issued (in shares)	56,672,658	56,672,658	56,672,658
Redeemable convertible preferred stock, shares outstanding (in shares)	56,672,658	56,672,658	56,672,658
Redeemable convertible preferred stock, liquidation value	$ 12,898,697,000	$ 12,898,697,000	$ 12,898,697,000
Series B Redeemable Convertible Preferred Stock [Member]
Redeemable convertible preferred stock, par value	$ 1	$ 1	$ 1
Redeemable convertible preferred stock, shares authorized (in shares)	51,069,262	51,069,262	51,069,262
Redeemable convertible preferred stock, shares issued (in shares)	51,069,262	51,069,262	51,069,262
Redeemable convertible preferred stock, shares outstanding (in shares)	51,069,262	51,069,262	51,069,262
Redeemable convertible preferred stock, liquidation value	$ 16,000,000,000	$ 16,000,000,000	$ 16,000,000,000

Statements of Operations

Statements of Operations - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Operating expenses
Research and development	$ 1,331	$ 686	$ 2,137	$ 8,722
General and administrative	863	694	2,982	2,341
Grant reimbursements	(94)
Total operating expenses, net	2,100	1,380	5,119	11,063
Loss from operations	(2,100)	(1,380)	(5,119)	(11,063)
Interest expense, net	(268)	(143)	(992)	(515)
Other income (expense), net	(94)		126	17
Net loss	$ (2,462)	$ (1,523)	$ (5,985)	$ (11,561)

Statements of Convertible Redee

Statements of Convertible Redeemable Preferred Stock and Stockholders' Deficit - USD ($) $ in Thousands	Preferred Stock [Member]Series A Redeemable Convertible Preferred Stock [Member]	Preferred Stock [Member]Series B Redeemable Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2016	56,321,165	51,069,262	19,548,969
Balance at Dec. 31, 2016	$ 12,734	$ 15,897	$ 20	$ 118	$ (19,733)	$ (19,595)
Exercise of warrants (in shares)	351,493
Exercise of warrants	$ 80
Stock-based compensation expense				301		301
Net loss					(11,561)	(11,561)
Balance (in shares) at Dec. 31, 2017	56,672,658	51,069,262	19,548,969
Balance at Dec. 31, 2017	$ 12,814	$ 15,897	$ 20	419	(31,294)	(30,855)
Stock-based compensation expense				75		75
Net loss					(1,523)	(1,523)
Balance (in shares) at Mar. 31, 2018	56,672,658	51,069,262	19,548,969
Balance at Mar. 31, 2018	$ 12,814	$ 15,897	$ 20	494	(32,817)	(32,303)
Balance (in shares) at Dec. 31, 2017	56,672,658	51,069,262	19,548,969
Balance at Dec. 31, 2017	$ 12,814	$ 15,897	$ 20	419	(31,294)	(30,855)
Stock-based compensation expense				309		309
Net loss					(5,985)	(5,985)
Balance (in shares) at Dec. 31, 2018	56,672,658	51,069,262	19,548,969
Balance at Dec. 31, 2018	$ 12,814	$ 15,897	$ 20	728	(37,279)	(36,531)
Stock-based compensation expense				84		84
Net loss					(2,462)	(2,462)
Balance (in shares) at Mar. 31, 2019	56,672,658	51,069,262	19,548,969
Balance at Mar. 31, 2019	$ 12,814	$ 15,897	$ 20	$ 812	$ (39,741)	$ (38,909)

Statement of Cash Flows

Statement of Cash Flows - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net loss	$ (2,462,000)	$ (1,523,000)	$ (5,985,000)	$ (11,561,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	2,000	2,300	8,000	10,000
Stock-based compensation expense	84,000	75,000	309,000	301,000
Changes in fair value of warrant liability	94,000		98,000	(12,000)
Accretion of final charge upon maturity of Oxford Term Loan A and B	80,000	27,000	224,000	106,000
Amortization of issuance cost and discounts for term loans and convertible notes	8,000	18,000	40,000	54,000
Non-cash interest expense on convertible promissory notes	89,000	1,000	126,000
Amortization of right-of-use asset	8,000
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(386,000)	(19,000)	23,000	329,000
Other assets				1,000
Accounts payable	710,000	(629,000)	(212,000)	601,000
Accrued liabilities	167,000	(387,000)	(650,000)	(12,000)
Net Cash Used in Operating Activities	(1,606,000)	(2,435,000)	(6,019,000)	(10,183,000)
Cash flows from investing activities:
Purchases of property and equipment			(5,000)	(3,000)
Net cash used in investing activities			(5,000)	(3,000)
Cash flows from financing activities:
Payments on term loan		(616,000)	(890,000)	(139,000)
Proceeds from exercise of warrants				80,000
Proceeds from issuance of convertible promissory notes - related party	1,500,000	1,500,000	4,500,000
Net cash provided (used) by financing activities	1,500,000	884,000	3,610,000	(59,000)
Net decrease in cash and cash equivalents and restricted cash	(106,000)	(1,551,000)	(2,414,000)	(10,245,000)
Cash and cash equivalents and restricted cash at beginning of year	1,942,000	4,356,000	4,356,000	14,601,000
Cash and cash equivalents and restricted cash at end of year	1,836,000	2,805,000	1,942,000	4,356,000
Other supplemental disclosure:
Cash paid for interest	91,000	97,000	376,000	355,000
Non-cash investing and financing activities
Right-of-use assets obtained in exchange for operating lease obligations(1)	$ 227,000

Note 1 - Organization and Basis

Note 1 - Organization and Basis of Presentation	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	Note 1. Organization and Basis of Presentation The Company Adynxx, Inc. (the "Company") was incorporated on October 24, 2007, Basis of Presentation The accompanying financial statements have been prepared using accounting principles generally accepted in the United States of America (“GAAP”). Unaudited Interim Financial Information The accompanying interim balance sheet as of March 31, 2019, three March 31, 2019 2018, March 31, 2019 three March 31, 2019 2018 three March 31, 2019 not 2019 Liquidity The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As of March 31, 2019, $1.6 $4.3 $6.2 March 31, 2019 $39.7 not no In April 2019 May 2019, $2 $0.5 8% first The Company plans to finance its operations and capital funding needs through equity and/or debt financing. However, there can be no one The accompanying financial statements do not

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2. S ummary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses incurred during the reporting period. Actual results could differ from those estimates and such differences could be material to the Company’s financial position and results of operations. Significant estimates and assumptions include the valuation of equity instruments and equity-linked instruments, including the valuation of the Company’s common stock and the valuation of the Company’s common stock options for purposes of accounting for stock-based compensation, and accruals for clinical trials and the valuation allowances on deferred tax assets. Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Cash and cash equivalents are deposited in demand and money market accounts with established financial institutions and, at times, such balances with any one may not The Company operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Company's future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Company's products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company's ability to attract and retain employees necessary to support its growth. The Company’s postoperative pain reduction product candidate, brivoligide, is an oligonucleotide. The Company currently uses Avecia as a single supplier for the brivoligide drug substance. There are currently a limited number of oligonucleotide manufacturers with commercial scale capabilities globally. While the Company intends to develop secondary sources for manufacturing of its drug candidates in the future, there can be no March 31, 2019, not At March 31, 2019, three 37%, 31% 14% 51% May 3, 2019, December 31, 2018, three 52%, 26% 15% 67% December 31, 2017, two 56% 31%, 56% Clinical Trial Accruals The Company’s clinical trial accruals are based on patient enrollment and related costs at clinical investigator sites as well as for the services received and efforts expended pursuant to contracts with multiple research institutions and contract research organizations that conduct and manage clinical trials on the Company’s behalf. The Company accrues expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity according to the clinical trial protocol. If timelines or contracts are modified based upon changes in the clinical trial protocol or scope of work to be performed, the Company modifies the estimates of accrued expenses accordingly. To date, the Company has had no In March 2018, 2 March 2018. December 31, 2018 2017, $95,000 $6.2 In November 2018, 2 $667,000 $0 three March 31, 2019 2018, $185,000 $0 December 31, 2018 2017, Cash and Cash Equivalents The Company considers all highly liquid investments purchased with a maturity of three Property and Equipment, Net Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using a straight-line method over the estimated useful lives of the assets, generally three five Expenditures for repairs and maintenance are charged to expense as incurred. Upon disposition of an asset, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is reflected in the statements of operations. Impairment of Long-Lived Assets The Company's long-lived assets and other assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not March 31, 2019, December 31, 2018 December 31, 2017, not Restricted Cash As of March 31, 2019, December 31, 2018 December 31, 2017, $255,000, $55,000 $55,000 March 31, 2019, $200,000 January 2019. March 31, 2019, December 31, 2018 December 31, 2017, $55,000 Stock-Based Compensation Stock-based compensation is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes forfeitures as they occur. The Company uses the Black-Scholes option-pricing model (the "Black-Scholes model") as the method for determining the estimated fair value of stock options. Expected Term - Expected Volatility - Expected Dividend - no Risk-Free Interest Rate - zero Research and Development Research and development expenses consist of personnel costs, including salaries, benefits and stock-based compensation, preclinical studies, clinical studies performed by Contract Research Organizations (or “CROs”), materials and supplies, licenses and fees, and overhead allocations consisting of various administrative and facilities related costs. The Company charges research and development costs, including clinical study costs, to expense when incurred. Collaboration Agreement In June 2018, March 31, 2019, not May 2019, $75,000, three June 30, 2019. Grant Reimbursements In December 2018, two December 2020 $5.7 On January 1, 2019, 2018 08, may not For the three March 31, 2019, $94,000 Income Taxes The Company accounts for income taxes using the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance, which would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not The Company recognizes the tax benefit from uncertain tax positions in accordance with GAAP, which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company's tax return. Convertible Preferred Stock Warrants Freestanding warrants to acquire shares of convertible preferred stock are classified as liabilities on the accompanying balance sheets. These warrants are subject to remeasurement at fair value at each balance sheet date, and any change in fair value is recognized as a component of other income or expense. The Company will continue to adjust the carrying values of freestanding warrants classified as liabilities for changes in fair value until the earlier of the exercise or expiration of the warrants or the completion of a liquidation event, including the completion of an initial public offering. Debt Modifications and Extinguishments When the Company modifies debt, it does so in accordance with Accounting Standards Codification (“ASC”) 470 50, Debt: Modifications and Extinguishments October 2018 March 2018 September 2018 $11,000 not Derivative Instruments ASC 815 15, Derivatives and Hedging: Embedded Derivatives three three not not 815. The Company issued certain Notes in March 2018, September 2018, December 2018 March 2019, 1 2 These embedded features were not In October 2018, March 2018 September 2018 “substantial modification” 470 50 ‘Debt: Modifications and Extinguishments’ As of March 31, 2019 December 31, 2018, no March 2018 September 2018, December 2018 March 2019 ‘Note 5 - Term Loans and Convertible Promissory Notes’ Fair Value of Financial Instruments ASC 820 10, Fair Value Measurement three may Level 1 Level 2 - 1 Level 3 - This hierarchy requires the use of observable market data when available and to minimize the use of unobservable inputs when determining fair value. The following tables present the Company’s fair value hierarchy for all of its financial instruments measured at fair value on a recurring basis as of March 31, 2019, December 31, 2018 December 31, 2017 ( As of December 31 , 201 7 Level 1 Level 2 Level 3 Total Financial liabilities: Warrant liability $ — $ — $ 42 $ 42 Total financial liabilities $ — $ — $ 42 $ 42 As of December 31, 201 8 Level 1 Level 2 Level 3 Total Financial liabilities: Warrant liability $ — $ — $ 140 $ 140 Total financial liabilities $ — $ — $ 140 $ 140 As of March 31, 2019 (unaudited) Level 1 Level 2 Level 3 Total Financial liabilities Warrant liability $ — $ — $ 234 $ 234 Total financial liabilities $ — $ — $ 234 $ 234 The carrying amounts reported in the accompanying balance sheets for cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their short maturities. The fair value of the Company’s term loan is based on the borrowing rate currently available to the Company for borrowings with similar terms and maturity and approximates its carrying value. Derivative liability instruments are considered Level 3 one 3 no The fair value of the warrant liability was determined using the Black-Scholes model (see ‘ Note 8 - Warrants ’ Years Ended December 31, Three Months Ended March 31, 2017 2018 2018 2019 (unaudited) (unaudited) Fair value, beginning of period $ 54 $ 42 $ 42 $ 140 Preferred stock warrants – exercised (8 ) — — — Change in fair value of preferred stock warrants (4 ) 98 — 94 Fair value at end of period $ 42 $ 140 $ 42 $ 234 The fair value of the embedded derivative liability related to the Company’s Notes was determined using a bond plus option model. As of March 31, 2019 December 31, 2018, no March 2018, September 2018, December 2018 March 2019 Note 5 - Term Loans and Convertible Promissory Notes ’ The change in fair value of the derivative liability relating to the Notes is summarized below (in thousands): Years Ended December 31, Three Months Ended March 31, 2017 2018 2018 2019 (unaudited) (unaudited) Fair value, beginning of period $ — — $ — $ — Embedded derivative liability from the issuance of Notes — 864 496 — Change in value of embedded derivatives — (211 ) — — Termination of the embedded derivative liability due to the extinguishment of the related Notes — (653 ) — — Fair value at end of period $ — — $ 496 $ — Recently Adopted Accounting Pronouncements Restricted Cash In November 2016, No. 2016 18, one December 15, 2017 January 1, 2018 Non-employee Share-Based Payment Accounting In June 2018, No. 2018 07, 718 2018 07" January 1, 2018 not Lease Accounting In February 2016, No. 2016 02, 842 2016 02” 2016 02 twelve 2016 02 December 15, 2018 may 1 2 January 1, 2019 not The Company has elected the package of practical expedients permitted in ASC Topic 842. 842, 842, 842 The most significant impact from the adoption of this standard was the recognition of ROU assets and lease obligations on the balance sheet for operating leases. This standard did not January 1, 2019 $227,000, $239,000, 9.41%, $227,000 $227,000. twelve January 1, 2019. Recent Accounting Pronouncements Not In August 2018, No. 2018 13, 820 December 15, 2019,

Note 3 - Property and Equipment

Note 3 - Property and Equipment, Net	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 3. Property and Equipment, Net Property and equipment, net, consist of the following (in thousands): As of December 31, As of March 31, 2017 2018 2019 (unaudited) Furniture and fixtures $ 29 $ 29 $ 29 Office equipment 2 2 2 Computer equipment 24 18 18 Laboratory equipment 2 2 2 Total property and equipment 57 51 51 Less accumulated depreciation (44 ) (41 ) (43 ) Property and equipment, net $ 13 $ 10 $ 8 Depreciation expense for the three March 31, 2019 2018 $2,300 $2,000, December 31, 2018 2017, $8,000 $10,000,

Note 4 - Accrued Liabilities

Note 4 - Accrued Liabilities	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 4. ccrued Liabilities Accrued liabilities consist of the following (in thousands): As of December 31, As of March 31, 2017 2018 2019 (unaudited) Payroll and related expenses $ 273 $ 241 $ 390 Accrued term loan final payment 197 421 501 Accrued clinical trial expense 654 — 17 Professional fees and other costs 34 195 285 Total accrued liabilities $ 1,158 $ 857 $ 1,193

Note 5 - Term Loans and Convert

Note 5 - Term Loans and Convertible Promissory Notes	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 5. Term Loans and Convertible Promissory Notes Term Loans On November 24, 2015, $10.0 three $3.0 $2.0 $5.0 November 24, 2015, $3.0 January 29, 2016, $2.0 Note 8 - Warrants may, $5.0 30 March 31, 2016. not March 31, 2016 $5.0 All outstanding Term Loans will mature on November 1, 2019 ( November 1, 2016, 36 7.06% 30 0.19%. The Company has the option to prepay all, but not 3% first 1% six 2% second 1% 4.25% The Company may first In January 2017, December 1, 2016 January 1, 2017, 12 23 $100,000. In March 2018, January 1, 2018, February 1, 2018 March 1, 2018 5 15 $200,000. In September 2018, 1 $1.5 2 11 $25,000. In December 2018, 1 $1.5 December 31, 2018, 10 $35,000. The amendment fees are due and payable upon the earlier of: (i) the Maturity Date, (ii) the acceleration of any Term Loan, or (iii) the prepayment of a Term Loan, and are being accrued over the expected term of the Term Loan as interest expense. In January 2019, 2 8 February 1, 2019 $20.0 $200,000 March 31, 2019 $200,000 March 31, 2019. $50,000. In May 2019, seventh Upon the respective dates of the debt modifications, no The Term Loan A was recorded at its initial carrying value of $3.0 $141,000, $2.0 $3,000. December 31, 2018, $2.3 $1.5 December 31, 2017, $2.8 $1.9 Interest expense recorded for the three March 31, 2019 2018 $179,000 $139,000, December 31, 2018 2017 $644,000 $515,000, As of March 31, 2019, Future principal payments for the Term Loans due under the Loan Agreement as of March 31, 2019, Year End ing , December 31, 2019 Total principal payments $ 3,833 Convertible Promissory Notes The table below reflects the principal amount of the Notes issued by the Company to current investors (in thousands): As of December 31, As of March 31, 2017 2018 2019 (unaudited) Convertible note payable, due on March 29, 2019 interest at 8.0% p.a. $ — $ 1,500 $ 1,500 Convertible note payable, due on September 27, 2019 interest at 8.0% p.a. — 1,500 1,500 Convertible note payable, due on December 21, 2019 interest at 8.0% p.a. — 1,500 1,500 Convertible note payable, due on March 29, 2020 interest at 8.0% p.a. — — 1,500 Total $ — $ 4,500 $ 6,000 Conversion rights The March 2019 December 2018 (a) in the event that the Company issues and sells shares of its preferred stock to the investors with proceeds to the Company of at least $5 (b) in the event that the Company issues and sells shares of its common stock to the investors with proceeds to the Company of at least $5 (c) in the event of a preferred stock financing after the Company’s Board of Directors (the “Board”) has determined that the Company should not not eighty 80% (d) if the Company consummates a change of control while the Notes remain outstanding, the Company shall repay the holders in cash in an amount equal to 200% (e) in the event the Company consummates an IPO on or before the maturity date, then the outstanding principal amount of the Notes and any unpaid accrued interest will automatically convert into common stock at a conversion price equal to the per share offering price to the public for common stock in the IPO. The Modified March 2018 September 2018 March 31, 2019, (a) in the event that the Company issues and sells shares of its preferred stock to the investors on or before the maturity date, in a preferred stock financing, then the outstanding principal amount of this convertible promissory note and any unpaid accrued interest will automatically convert in whole into equity securities sold in the qualified financing at a conversion price equal to 80% (b) if the Company consummates a change of control while the Notes remain outstanding, the Company shall repay the holders in cash in an amount equal to 200% (c) in the event the Company consummates an IPO on or before the maturity date, then the outstanding principal amount of the Notes and any unpaid accrued interest will automatically convert into common stock at a conversion price equal to the per share offering price to the public for common stock in the IPO. (d) In October 2018, March 2018 September 2018 $0.3133 In October 2018, March 2018 September 2018 470 50 Debt: Modifications and Extinguishments ’ $11,000 In May 2019, March 2018 September 2018 Derivative Liability The Company evaluated its Notes and determined that embedded components relating to conversion and redemption features of those contracts qualified as derivatives, which need to be separately accounted for in accordance with ASC 815. 1. On or before the maturity date of the March 2018 September 2018 $5.0 80% not 2. For all Notes, in the event of a change in control prior to repayment, the outstanding principal and unpaid accrued interest will be repaid in cash, plus a repayment premium equal to 100% 50% not 3. For the March 2019 December 2018 not not $5.0 80% not not Accordingly, upon the issuance of the March 2018 30% 15% $496,000 one Upon the issuance of the September 2018 40% zero $368,000 one In October 2018, March 2018 September 2018 “substantial modification 470 50 ‘Debt: Modifications and Extinguishments’ March 2018 September 2018 $11,000 $641,000 $653,000.As March 31, 2019 December 31, 2018, March 2018, September 2018, December 2018 March 2019 no zero not zero $0 December 31, 2018 March 31, 2019. For the three March 31, 2019 2018, December 31, 2018, December 31, 2017, $0, $4,000, $223,000 $0,

Note 6 - Commitments and Contin

Note 6 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 6. Commitments and Contingencies Operating Leases The Company leases office facilities under a non-cancelable operating lease agreement expiring on December 31, 2019. March 31, 2019 Year ending December 31 Future Commitments (unaudited) 2019 (remaining 9 months) $ 180 Total $ 180 Rent expense related to the Company's operating leases was $67,000 $57,000 three March 31, 2019 2018, $232,000 $225,000 December 31, 2018 December 31, 2017, Indemnifications The Company has agreed to indemnify its directors and officers for certain events or occurrences arising as a result of the officers or directors serving in such capacity. The Company has a directors' and officers’ liability insurance policy that limits its exposure and enables the Company to recover a portion of any future amounts paid resulting from the indemnification of its officers and directors. The Company has not not March 31, 2019, December 31, 2018 December 31, 2017.

Note 7 - Stockholders' Deficit

Note 7 - Stockholders' Deficit	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 7. Stockholders’ Deficit Redeemable Convertible Preferred Stock As of March 31, 2019, December 31, 2018 December 31, 2017, 56,672,658 3,531,889 2010. March 31, 2019, December 31, 2018 December 31, 2017, 51,069,262 6,469,356 2016. The holders of preferred stock have various rights and preferences including the following: Voting Rights - one two one 10,000,000 two Dividends - $0.0251 $0.0182 No three March 31, 2019 2018 December 31, 2018 2017. Liquidation Preference - $0.3133 After distributions have been made to all holders of Series B convertible preferred stock as described above, the remaining assets of the Company available for distribution to stockholders shall be distributed to all holders of Series A convertible preferred stock. The holders of Series A convertible preferred stock are entitled to receive an amount of $0.2276 Conversion Rights - one one 1 $40 not $1.00 2 The Series A and Series B Preferred Stock were classified as temporary equity in the accompanying balance sheets as of the March 31, 2019, December 31, 2018 2017, not March 31, 2019, December 31, 2018, 2017, not Common Stock The Company's articles of incorporation, as amended, authorize the Company to issue 148,000,000 $0.001 March 31, 2019, December 31, 2018 December 31, 2017, 19,548,969 one March 31, 2019 December 31, 2018, no Shares Reserved for Future Issuance The Company reserved shares of common stock for future issuances as follows (in thousands): As of December 31, As of March 31, 2017 2018 2019 (unaudited) Series A convertible preferred stock 56,673 56,673 56,673 Series B convertible preferred stock 51,069 51,069 51,069 Warrants for Series A convertible preferred stock 330 330 330 Common stock options issued and outstanding 19,222 19,222 19,222 Total 127,294 127,294 127,294

Note 8 - Warrants

Note 8 - Warrants	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Warrants Disclosure [Text Block]	Note 8 . Warrants In connection with convertible notes agreements with investors issued between January 1, 2009 July 1, 2010, 20% five seven 3.92 7 1.46% 2.66%, 73.6% 81.5%, $0.2276 December 31, 2017, In connection with the Oxford Loan Agreement signed in November 2015, 197,715 $0.2276. ten 10 2.07%, 68.7%, $0.20 $33,000 In January 2016, November 2015, 131,810 $0.2276. ten 10 2.09%, 68.6%, $0.23 $22,000 The change in fair value of the warrants issued in connection with Term Loan A and B at March 31, 2019, December 31, 2018 2017 $95,000, $98,000 $4,000 March 31, 2019, The above Black-Scholes model assumptions were determined as follows: Term Risk-free interest rate – zero Expected volatility no Expected dividend yield not The warrants are classified as a liability as they are exercisable into shares that are potentially redeemable. The fair value of the warrant liability is re-measured at each balance sheet date with the change as other income recorded in the statements of operations. The fair value of the Series A convertible preferred stock warrants outstanding at March 31, 2019, December 31, 2018 December 31, 2017 $234,000, $140,000 $42,000 Issuance Date Expiration Date Exercise Price Number of Shares (000's) November, 2015 November, 2025 0.2276 198 June, 2016 January, 2026 0.2276 132 Total 330 The fair value of the Series A convertible preferred stock warrants was determined using the following assumptions: As of December 31, As of March 31, 2017 2018 2019 (unaudited) Risk-free interest rate 2.28% 2.56% - 2.59% 2.27% - 2.28 Remaining contractual life (in years) 7.92 - 8.08 6.92 - 7.08 6.67 - 6.83 Dividend yield — — — Expected volatility 71.00% 76.84% 84.44%

Note 9 - Stock Option Plans

Note 9 - Stock Option Plans	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	Note 9. Stock Option Plans In December 2010, 2010 may may may 19,222,032 December 31, 2018. Options under the Plan may 10 no 100% 10% not 110% no 10 four The following table summarizes stock option activity under the Company’s stock plan and related information (in thousands, except exercise prices and years): Outstanding Options Shares Available For Grant Options Outstanding Weighted Average Exercise Price Per Share Weighted- Average Remaining Contractual Life (in years) Aggregate Intrinsic (a) Balance at December 31, 2016 5 19,222 $ 0.10 9.4 Balance at December 31, 2017 5 19,222 $ 0.10 8.4 $ 6,639 Balance at December 31, 2018 5 19,222 $ 0.10 7.4 $ 6,956 Vested and expected to vest as of December 31, 2018 19,222 $ 0.10 7.4 $ 6,956 Exercisable at December 31, 2018 11,146 $ 0.09 7.4 $ 4,119 (a) The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the estimated fair value of the Company’s common stock of $$0.46 $0.44 December 31, 2018 2017. The Company did not three March 31, 2019 December 31, 2018 2017. $68,000 $75,000 three March 31, 2019 2018, $293,000 $301,000 December 31, 2018 2017, March 31, 2019, $463,000, 1.75 Stock Options Granted to Non-Employees. Stock-based compensation expense recorded in exchange for services related to non-employee options was $16,000 $0 three March 31, 2019 2018, $16,000 $0 December 31, 2018 2017, As of March 31, 2019, $32,000, six

Note 10 - Income Taxes

Note 10 - Income Taxes	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 1 0. Income Taxes The Company recorded no three March 31, 2019 2018, December 31, 2018 2017. No March 31, 2019 not not Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The following table presents significant components of the Company’s deferred tax assets (in thousands): As of December 31, 2017 2018 Net operating loss carry forward $ 6,158 $ 7,051 Research and development credits 1,284 1,601 Accruals and reserves 99 142 Fixed assets — 1 Total deferred tax asset 7,541 8,795 Valuation allowance (7,541 ) (8,795 ) Net deferred tax asset $ — $ — The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on the Company’s history of operating losses, the Company has concluded that it is more likely than not not December 31, 2018 2017. $1.2 $964,000 December 31, 2018 2017, On December 22, 2017, 2017, not one 2018 not 35% 21% December 31, 2017, not one not During 2017, not not 2016 As of December 31, 2018, $33.5 January 1, 2018 $28.7 2033. December 31, 2017 $4.8 December 31, 2018, $1.8 $0.7 2031. Internal Revenue Code (“IRC”) Section 382 382 not 382 December 31, 2012, The tax return years 2014 2018 2013 2015 2018 2007 2013 2015 2018 ASC 740 10 not Years Ended December 31, 2018 Balance at December 31, 2017 $ 331 Changes related to prior year positions 330 Increases related to current year positions 42 Balance at December 31, 2018 $ 703 The Company’s policy is to record interest related to uncertain tax positions as interest and any penalties as other expense in its statement of operations. As of the date of adoption and through December 31, 2018, not

Note 11 - Related-party Transac

Note 11 - Related-party Transactions	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 1 1. Related-Party Transactions In March 2018, September 2018, December 2018 March 2019, $6.0 March 31, 2019. April 2019 May 2019, $2.0 $0.5 8% March 31, 2019, $215,000 ‘ Note 5 - Term Loans and Convertible Promissory Notes’ On May 3, 2019, $3.0 $203,000 10,223,996

Note 12 - Employee Benefit Plan

Note 12 - Employee Benefit Plan	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	Note 1 2. Employee Benefit Plan The Company has established a 401 "401 401 may, 401 no 401 401 3% $49,000 $54,000 December 31, 2018 2017, January 2019, 401 3%

Note 13 - Subsequent Events

Note 13 - Subsequent Events	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	Note 1 3 Subsequent Events In April 2019 May 2019, $2.0 $0.5 8% April 26, 2020 May 29, 2020. In May 2019, seventh On May 3, 2019 368 1986, 86% 14% Subject to the terms and conditions of the Merger Agreement (a) each outstanding share of capital stock of Adynxx, was converted into the right to receive the number of shares of Alliqua's common stock equal to the Exchange Ratio formula in the Merger Agreement and (b) each outstanding Adynxx stock option, whether vested or unvested, and warrant that has not may On May 3, 2019, $3.0 $203,000 10,223,996 The Company has evaluated subsequent events through June 7, 2019,

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses incurred during the reporting period. Actual results could differ from those estimates and such differences could be material to the Company’s financial position and results of operations. Significant estimates and assumptions include the valuation of equity instruments and equity-linked instruments, including the valuation of the Company’s common stock and the valuation of the Company’s common stock options for purposes of accounting for stock-based compensation, and accruals for clinical trials and the valuation allowances on deferred tax assets.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Cash and cash equivalents are deposited in demand and money market accounts with established financial institutions and, at times, such balances with any one may not The Company operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Company's future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Company's products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company's ability to attract and retain employees necessary to support its growth. The Company’s postoperative pain reduction product candidate, brivoligide, is an oligonucleotide. The Company currently uses Avecia as a single supplier for the brivoligide drug substance. There are currently a limited number of oligonucleotide manufacturers with commercial scale capabilities globally. While the Company intends to develop secondary sources for manufacturing of its drug candidates in the future, there can be no March 31, 2019, not At March 31, 2019, three 37%, 31% 14% 51% May 3, 2019, December 31, 2018, three 52%, 26% 15% 67% December 31, 2017, two 56% 31%, 56%
Clinical Trial Accruals, Policy [Policy Text Block]	Clinical Trial Accruals The Company’s clinical trial accruals are based on patient enrollment and related costs at clinical investigator sites as well as for the services received and efforts expended pursuant to contracts with multiple research institutions and contract research organizations that conduct and manage clinical trials on the Company’s behalf. The Company accrues expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity according to the clinical trial protocol. If timelines or contracts are modified based upon changes in the clinical trial protocol or scope of work to be performed, the Company modifies the estimates of accrued expenses accordingly. To date, the Company has had no In March 2018, 2 March 2018. December 31, 2018 2017, $95,000 $6.2 In November 2018, 2 $667,000 $0 three March 31, 2019 2018, $185,000 $0 December 31, 2018 2017,
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with a maturity of three
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment, Net Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using a straight-line method over the estimated useful lives of the assets, generally three five Expenditures for repairs and maintenance are charged to expense as incurred. Upon disposition of an asset, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is reflected in the statements of operations.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company's long-lived assets and other assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not March 31, 2019, December 31, 2018 December 31, 2017, not
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash As of March 31, 2019, December 31, 2018 December 31, 2017, $255,000, $55,000 $55,000 March 31, 2019, $200,000 January 2019. March 31, 2019, December 31, 2018 December 31, 2017, $55,000
Share-based Payment Arrangement [Policy Text Block]	Stock-Based Compensation Stock-based compensation is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes forfeitures as they occur. The Company uses the Black-Scholes option-pricing model (the "Black-Scholes model") as the method for determining the estimated fair value of stock options. Expected Term - Expected Volatility - Expected Dividend - no Risk-Free Interest Rate - zero
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development expenses consist of personnel costs, including salaries, benefits and stock-based compensation, preclinical studies, clinical studies performed by Contract Research Organizations (or “CROs”), materials and supplies, licenses and fees, and overhead allocations consisting of various administrative and facilities related costs. The Company charges research and development costs, including clinical study costs, to expense when incurred.
Collaborative Arrangement, Accounting Policy [Policy Text Block]	Collaboration Agreement In June 2018, March 31, 2019, not May 2019, $75,000, three June 30, 2019.
Grant Reimbursement, Policy [Policy Text Block]	Grant Reimbursements In December 2018, two December 2020 $5.7 On January 1, 2019, 2018 08, may not For the three March 31, 2019, $94,000
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes using the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance, which would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not The Company recognizes the tax benefit from uncertain tax positions in accordance with GAAP, which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company's tax return.
Convertible Preferred Stock Warrants, Policy [Policy Text Block]	Convertible Preferred Stock Warrants Freestanding warrants to acquire shares of convertible preferred stock are classified as liabilities on the accompanying balance sheets. These warrants are subject to remeasurement at fair value at each balance sheet date, and any change in fair value is recognized as a component of other income or expense. The Company will continue to adjust the carrying values of freestanding warrants classified as liabilities for changes in fair value until the earlier of the exercise or expiration of the warrants or the completion of a liquidation event, including the completion of an initial public offering.
Debt Modifications and Extinguishments, Policy [Policy Text Block]	Debt Modifications and Extinguishments When the Company modifies debt, it does so in accordance with Accounting Standards Codification (“ASC”) 470 50, Debt: Modifications and Extinguishments October 2018 March 2018 September 2018 $11,000 not
Derivatives, Policy [Policy Text Block]	Derivative Instruments ASC 815 15, Derivatives and Hedging: Embedded Derivatives three three not not 815. The Company issued certain Notes in March 2018, September 2018, December 2018 March 2019, 1 2 These embedded features were not In October 2018, March 2018 September 2018 “substantial modification” 470 50 ‘Debt: Modifications and Extinguishments’ As of March 31, 2019 December 31, 2018, no March 2018 September 2018, December 2018 March 2019 ‘Note 5 - Term Loans and Convertible Promissory Notes’
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments ASC 820 10, Fair Value Measurement three may Level 1 Level 2 - 1 Level 3 - This hierarchy requires the use of observable market data when available and to minimize the use of unobservable inputs when determining fair value. The following tables present the Company’s fair value hierarchy for all of its financial instruments measured at fair value on a recurring basis as of March 31, 2019, December 31, 2018 December 31, 2017 ( As of December 31 , 201 7 Level 1 Level 2 Level 3 Total Financial liabilities: Warrant liability $ — $ — $ 42 $ 42 Total financial liabilities $ — $ — $ 42 $ 42 As of December 31, 201 8 Level 1 Level 2 Level 3 Total Financial liabilities: Warrant liability $ — $ — $ 140 $ 140 Total financial liabilities $ — $ — $ 140 $ 140 As of March 31, 2019 (unaudited) Level 1 Level 2 Level 3 Total Financial liabilities Warrant liability $ — $ — $ 234 $ 234 Total financial liabilities $ — $ — $ 234 $ 234 The carrying amounts reported in the accompanying balance sheets for cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their short maturities. The fair value of the Company’s term loan is based on the borrowing rate currently available to the Company for borrowings with similar terms and maturity and approximates its carrying value. Derivative liability instruments are considered Level 3 one 3 no The fair value of the warrant liability was determined using the Black-Scholes model (see ‘ Note 8 - Warrants ’ Years Ended December 31, Three Months Ended March 31, 2017 2018 2018 2019 (unaudited) (unaudited) Fair value, beginning of period $ 54 $ 42 $ 42 $ 140 Preferred stock warrants – exercised (8 ) — — — Change in fair value of preferred stock warrants (4 ) 98 — 94 Fair value at end of period $ 42 $ 140 $ 42 $ 234 The fair value of the embedded derivative liability related to the Company’s Notes was determined using a bond plus option model. As of March 31, 2019 December 31, 2018, no March 2018, September 2018, December 2018 March 2019 Note 5 - Term Loans and Convertible Promissory Notes ’ The change in fair value of the derivative liability relating to the Notes is summarized below (in thousands): Years Ended December 31, Three Months Ended March 31, 2017 2018 2018 2019 (unaudited) (unaudited) Fair value, beginning of period $ — — $ — $ — Embedded derivative liability from the issuance of Notes — 864 496 — Change in value of embedded derivatives — (211 ) — — Termination of the embedded derivative liability due to the extinguishment of the related Notes — (653 ) — — Fair value at end of period $ — — $ 496 $ —
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements Restricted Cash In November 2016, No. 2016 18, one December 15, 2017 January 1, 2018 Non-employee Share-Based Payment Accounting In June 2018, No. 2018 07, 718 2018 07" January 1, 2018 not Lease Accounting In February 2016, No. 2016 02, 842 2016 02” 2016 02 twelve 2016 02 December 15, 2018 may 1 2 January 1, 2019 not The Company has elected the package of practical expedients permitted in ASC Topic 842. 842, 842, 842 The most significant impact from the adoption of this standard was the recognition of ROU assets and lease obligations on the balance sheet for operating leases. This standard did not January 1, 2019 $227,000, $239,000, 9.41%, $227,000 $227,000. twelve January 1, 2019. Recent Accounting Pronouncements Not In August 2018, No. 2018 13, 820 December 15, 2019,

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	As of December 31 , 201 7 Level 1 Level 2 Level 3 Total Financial liabilities: Warrant liability $ — $ — $ 42 $ 42 Total financial liabilities $ — $ — $ 42 $ 42 As of December 31, 201 8 Level 1 Level 2 Level 3 Total Financial liabilities: Warrant liability $ — $ — $ 140 $ 140 Total financial liabilities $ — $ — $ 140 $ 140 As of March 31, 2019 (unaudited) Level 1 Level 2 Level 3 Total Financial liabilities Warrant liability $ — $ — $ 234 $ 234 Total financial liabilities $ — $ — $ 234 $ 234
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Years Ended December 31, Three Months Ended March 31, 2017 2018 2018 2019 (unaudited) (unaudited) Fair value, beginning of period $ 54 $ 42 $ 42 $ 140 Preferred stock warrants – exercised (8 ) — — — Change in fair value of preferred stock warrants (4 ) 98 — 94 Fair value at end of period $ 42 $ 140 $ 42 $ 234 Years Ended December 31, Three Months Ended March 31, 2017 2018 2018 2019 (unaudited) (unaudited) Fair value, beginning of period $ — — $ — $ — Embedded derivative liability from the issuance of Notes — 864 496 — Change in value of embedded derivatives — (211 ) — — Termination of the embedded derivative liability due to the extinguishment of the related Notes — (653 ) — — Fair value at end of period $ — — $ 496 $ — Recently Adopted Accounting Pronouncements

Note 3 - Property and Equipme_2

Note 3 - Property and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Property, Plant and Equipment [Table Text Block]	As of December 31, As of March 31, 2017 2018 2019 (unaudited) Furniture and fixtures $ 29 $ 29 $ 29 Office equipment 2 2 2 Computer equipment 24 18 18 Laboratory equipment 2 2 2 Total property and equipment 57 51 51 Less accumulated depreciation (44 ) (41 ) (43 ) Property and equipment, net $ 13 $ 10 $ 8

Note 4 - Accrued Liabilities (T

Note 4 - Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	As of December 31, As of March 31, 2017 2018 2019 (unaudited) Payroll and related expenses $ 273 $ 241 $ 390 Accrued term loan final payment 197 421 501 Accrued clinical trial expense 654 — 17 Professional fees and other costs 34 195 285 Total accrued liabilities $ 1,158 $ 857 $ 1,193

Note 5 - Term Loans and Conve_2

Note 5 - Term Loans and Convertible Promissory Notes (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Long-term Debt Instruments [Table Text Block]	Year End ing , December 31, 2019 Total principal payments $ 3,833
Convertible Debt [Table Text Block]	As of December 31, As of March 31, 2017 2018 2019 (unaudited) Convertible note payable, due on March 29, 2019 interest at 8.0% p.a. $ — $ 1,500 $ 1,500 Convertible note payable, due on September 27, 2019 interest at 8.0% p.a. — 1,500 1,500 Convertible note payable, due on December 21, 2019 interest at 8.0% p.a. — 1,500 1,500 Convertible note payable, due on March 29, 2020 interest at 8.0% p.a. — — 1,500 Total $ — $ 4,500 $ 6,000

Note 6 - Commitments and Cont_2

Note 6 - Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year ending December 31 Future Commitments (unaudited) 2019 (remaining 9 months) $ 180 Total $ 180

Note 7 - Stockholders' Deficit

Note 7 - Stockholders' Deficit (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Stockholders Equity [Table Text Block]	As of December 31, As of March 31, 2017 2018 2019 (unaudited) Series A convertible preferred stock 56,673 56,673 56,673 Series B convertible preferred stock 51,069 51,069 51,069 Warrants for Series A convertible preferred stock 330 330 330 Common stock options issued and outstanding 19,222 19,222 19,222 Total 127,294 127,294 127,294

Note 8 - Warrants (Tables)

Note 8 - Warrants (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Issuance Date Expiration Date Exercise Price Number of Shares (000's) November, 2015 November, 2025 0.2276 198 June, 2016 January, 2026 0.2276 132 Total 330
Warrants for Series A Convertible Preferred Stock [Member]
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	As of December 31, As of March 31, 2017 2018 2019 (unaudited) Risk-free interest rate 2.28% 2.56% - 2.59% 2.27% - 2.28 Remaining contractual life (in years) 7.92 - 8.08 6.92 - 7.08 6.67 - 6.83 Dividend yield — — — Expected volatility 71.00% 76.84% 84.44%

Note 9 - Stock Option Plans (Ta

Note 9 - Stock Option Plans (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Outstanding Options Shares Available For Grant Options Outstanding Weighted Average Exercise Price Per Share Weighted- Average Remaining Contractual Life (in years) Aggregate Intrinsic (a) Balance at December 31, 2016 5 19,222 $ 0.10 9.4 Balance at December 31, 2017 5 19,222 $ 0.10 8.4 $ 6,639 Balance at December 31, 2018 5 19,222 $ 0.10 7.4 $ 6,956 Vested and expected to vest as of December 31, 2018 19,222 $ 0.10 7.4 $ 6,956 Exercisable at December 31, 2018 11,146 $ 0.09 7.4 $ 4,119

Note 10 - Income Taxes (Tables)

Note 10 - Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	As of December 31, 2017 2018 Net operating loss carry forward $ 6,158 $ 7,051 Research and development credits 1,284 1,601 Accruals and reserves 99 142 Fixed assets — 1 Total deferred tax asset 7,541 8,795 Valuation allowance (7,541 ) (8,795 ) Net deferred tax asset $ — $ —
Summary of Income Tax Contingencies [Table Text Block]	Years Ended December 31, 2018 Balance at December 31, 2017 $ 331 Changes related to prior year positions 330 Increases related to current year positions 42 Balance at December 31, 2018 $ 703

Note 1 - Organization and Bas_2

Note 1 - Organization and Basis of Presentation (Details Textual) - USD ($)	May 31, 2019	Apr. 30, 2019	May 31, 2019	May 30, 2019	Apr. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash and Cash Equivalents, at Carrying Value, Ending Balance						$ 1,581,000	$ 1,887,000	$ 4,301,000
Loans Payable, Total						4,300,000
Retained Earnings (Accumulated Deficit), Ending Balance						$ (39,741,000)	$ (37,279,000)	$ (31,294,000)
Majority Investors [Member]
Debt Instrument, Interest Rate, Stated Percentage						8.00%
Majority Investors [Member] | Subsequent Event [Member]
Proceeds from Notes Payable, Total				$ 500,000	$ 2,000,000
Majority Investors [Member] | First Note to Fund the Company's Operations [Member] | Subsequent Event [Member]
Proceeds from Notes Payable, Total		$ 2,000,000			$ 2,000,000
Majority Investors [Member] | Second Note to Fund the Company's Operations [Member] | Subsequent Event [Member]
Proceeds from Notes Payable, Total	$ 500,000		$ 500,000
Majority Investors [Member] | Notes to Fund the Company's Operations [Member] | Subsequent Event [Member]
Debt Instrument, Interest Rate, Stated Percentage	8.00%		8.00%
Convertible Debt [Member]
Notes Payable, Total						$ 6,200,000

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	1 Months Ended	3 Months Ended			12 Months Ended
	Oct. 31, 2018	Jun. 30, 2019	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Jan. 01, 2019
Research and Development Expense, Total			$ 1,331,000	$ 686,000	$ 2,137,000	$ 8,722,000
Impairment of Long-Lived Assets Held-for-use			0		0	0
Restricted Cash, Total			255,000		55,000	55,000
Payments of Dividends, Total			0
Grant Reimbursements			94,000
Gain (Loss) on Extinguishment of Debt, Total			11,000
Operating Lease, Liability, Total					180,000
Operating Lease, Right-of-Use Asset			165,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Liability, Total							$ 227,000
Lessee, Operating Lease, Liability, Payments, Due, Total							$ 239,000
Lessee, Operating Lease, Discount Rate							9.41%
Operating Lease, Right-of-Use Asset							$ 227,000
Modified March 2018 and Modified September 2018 Notes [Member]
Gain (Loss) on Extinguishment of Debt, Total	$ 11,000
Embedded Derivative, Fair Value of Embedded Derivative Asset			0		0
Embedded Derivative, Fair Value of Embedded Derivative Liability			0		0
Research and Development Expense [Member] | Subsequent Event [Member]
Collaboration Initiation Payment		$ 75,000
Money Market Funds [Member]
Restricted Cash, Total			200,000
Letter of Credit 1 [Member]
Restricted Cash, Total			$ 55,000		55,000	55,000
Minimum [Member]
Property, Plant and Equipment, Useful Life			3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life			5 years
Grants Receivable					5,700,000
Clinical Study, Premier Research International LLC and CRF Health, Inc. [Member]
Research and Development Expense, Total					95,000	6,200,000
Clinical Study, PRA Health, CRF Health, Inc., Premier Research International LLC, ICON Central Laboratories, and Almac Clinical Services [Member]
Research and Development Expense, Total			$ 667,000	$ 0	$ 185,000	$ 0
Accounts Payable 1 [Member] | Supplier Concentration Risk [Member] | Vendor 1 [Member]
Concentration Risk, Percentage			37.00%		52.00%	56.00%
Accounts Payable 1 [Member] | Supplier Concentration Risk [Member] | Vendor 2 [Member]
Concentration Risk, Percentage			31.00%		26.00%	31.00%
Accounts Payable 1 [Member] | Supplier Concentration Risk [Member] | Vendor 3 [Member]
Concentration Risk, Percentage			14.00%		15.00%
Accounts Payable 1 [Member] | Supplier Concentration Risk [Member] | Two of the Three Vendors Supporting Clinical Study Activities [Member]
Concentration Risk, Percentage			51.00%		67.00%
Accounts Payable 1 [Member] | Supplier Concentration Risk [Member] | One of the Two Vendors Supporting Manufacturing Activities [Member]
Concentration Risk, Percentage						56.00%

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Fair Value Measurements Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Total financial liabilities	$ 234	$ 140	$ 42
Fair Value, Inputs, Level 1 [Member]
Total financial liabilities
Fair Value, Inputs, Level 2 [Member]
Total financial liabilities
Fair Value, Inputs, Level 3 [Member]
Total financial liabilities	234	140	42
Warrant [Member]
Warrant liability	234	140	42
Warrant [Member] | Fair Value, Inputs, Level 1 [Member]
Warrant liability
Warrant [Member] | Fair Value, Inputs, Level 2 [Member]
Warrant liability
Warrant [Member] | Fair Value, Inputs, Level 3 [Member]
Warrant liability	$ 234	$ 140	$ 42

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Change in Fair Value of Preferred Stock Warrant Liability (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Warrant [Member]
Fair value, beginning of period	$ 140	$ 42	$ 42	$ 54
Preferred stock warrants – exercised				(8)
Change in fair value of preferred stock warrants	94		98	(4)
Fair value at end of period	234	42	140	42
Derivative [Member]
Fair value, beginning of period
Change in fair value of preferred stock warrants			(211)
Embedded derivative liability from the issuance of Notes		496	864
Termination of the embedded derivative liability due to the extinguishment of the related Notes			(653)
Fair value at end of period		$ 496

Note 3 - Property and Equipme_3

Note 3 - Property and Equipment, Net (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Depreciation, Total	$ 2,000	$ 2,300	$ 8,000	$ 10,000

Note 3 - Property and Equipme_4

Note 3 - Property and Equipment, Net -Property and equipment, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Property and equipment, gross	$ 51	$ 51	$ 57
Less accumulated depreciation	(43)	(41)	(44)
Property and equipment, net	8	10	13
Furniture and Fixtures [Member]
Property and equipment, gross	29	29	29
Office Equipment [Member]
Property and equipment, gross	2	2	2
Computer Equipment [Member]
Property and equipment, gross	18	18	24
Laboratory Equipment [Member]
Property and equipment, gross	$ 2	$ 2	$ 2

Note 4 - Accrued Liabilities -

Note 4 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Payroll and related expenses	$ 390	$ 241	$ 273
Accrued term loan final payment	501	421	197
Accrued clinical trial expense	17		654
Professional fees and other costs	285	195	34
Total accrued liabilities	$ 1,193	$ 857	$ 1,158

Note 5 - Term Loans and Conve_3

Note 5 - Term Loans and Convertible Promissory Notes (Details Textual) - USD ($)	Sep. 27, 2018	Mar. 29, 2018	Nov. 01, 2016	Mar. 31, 2016	Jan. 29, 2016	Nov. 24, 2015	Jan. 31, 2019	Dec. 31, 2018	Oct. 31, 2018	Sep. 30, 2018	Mar. 31, 2018	Jan. 31, 2017	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Restricted Cash, Total								$ 55,000					$ 255,000		$ 55,000	$ 55,000
Interest Expense, Total													179,000	$ 139,000	644,000	515,000
Gain (Loss) on Extinguishment of Debt, Total													11,000
Modified March 2019 and Modified December 2018 Notes [Member]
Debt Instrument, Convertible, Preferred Stock Proceeds Trigger													5,000,000
Debt Instrument, Convertible, Common Stock Proceeds Trigger													$ 5,000,000
Debt Instrument, Convertible, Conversion Ratio													8000.00%
Debt Instrument, Conversion to Cash in Case of Change in Control													200.00%
Financing Threshold, Proceeds to Convert Notes to Equity													$ 5,000,000
Modified March 2018 and Modified September 2018 Notes [Member]
Debt Instrument, Convertible, Conversion Ratio													8000.00%
Debt Instrument, Conversion to Cash in Case of Change in Control													200.00%
Gain (Loss) on Extinguishment of Debt, Total									$ 11,000
Financing Threshold, Proceeds to Convert Notes to Equity													$ 5,000,000
Debt Instrument, Conversion to Cash in Case of Change in Control, Premium													100.00%
Voting Rights Transferred to be Considered a Change in Control													50.00%
Embedded Derivative, Fair Value of Embedded Derivative Liability								0					$ 0		0
Amortization of Debt Discount (Premium)									641,000
Release of Derivative Liabilities									$ 653,000
Modified March 2018 and Modified September 2018 Notes [Member] | Convert Notes and Accrued Interest to Series B Preferred Stock [Member]
Debt Instrument, Convertible, Conversion Price									$ 0.3133
Convertible Promissory Note Issued on March 29, 2019 [Member]
Probability of Qualified Financing Occurring		30.00%
Probability of Change in Control Occurring		15.00%
Embedded Derivative, Fair Value of Embedded Derivative Liability		$ 496,000
Debt Instrument, Convertible, Remaining Discount Amortization Period		1 year
Debt Instrument, Unamortized Discount, Current		$ 496,000
Convertible Promissory Note Issued September 27, 2018 [Member]
Probability of Qualified Financing Occurring	40.00%
Probability of Change in Control Occurring	0.00%
Embedded Derivative, Fair Value of Embedded Derivative Liability	$ 368,000
Debt Instrument, Convertible, Remaining Discount Amortization Period	1 year
Debt Instrument, Unamortized Discount, Current	$ 369,000
Modified March 2018, September 2018, December 2018, and March 2019 Notes [Member]
Probability of Qualified Financing Occurring									0.00%
Probability of Change in Control Occurring									0.00%
Embedded Derivative, Fair Value of Embedded Derivative Liability									$ 0
Amortization of Debt Discount (Premium)													0	4,000	223,000	0
Oxford Finance, LLC [Member]
Debt Instrument, Face Amount						$ 10,000,000
Oxford Finance, LLC [Member] | Term Loan A [Member]
Debt Instrument, Face Amount						3,000,000
Proceeds from Issuance of Debt						3,000,000
Debt Issuance Costs, Net, Total						141,000
Long-term Debt, Total								2,300,000							2,300,000	2,800,000
Oxford Finance, LLC [Member] | Term Loan B [Member]
Debt Instrument, Face Amount						2,000,000
Proceeds from Issuance of Debt					$ 2,000,000
Debt Issuance Costs, Net, Total						3,000
Long-term Debt, Total								1,500,000							1,500,000	$ 1,900,000
Oxford Finance, LLC [Member] | Term Loan C [Member]
Debt Instrument, Face Amount						$ 5,000,000
Proceeds from Issuance of Debt				$ 0
Debt Instrument, Unused Borrowing Capacity, Amount				5,000,000
Debt Instrument, Unused Borrowing Capacity, Expired				$ 5,000,000
Oxford Finance, LLC [Member] | Term Loans [Member]
Long-term Debt, Principal and Interest Payments, Term			3 years
Debt Instrument, Interest Rate, Stated Percentage						7.06%
Debt Instrument, Prepayment Fee Before First Anniversary,Percentage						3.00%
Debt Instrument, Prepayment Fee if Company is Acquired Within Six Months of Closing, Percentage						1.00%
Debt Instrument, Prepayment Fee Between First and Second Anniversary, Percentage						2.00%
Debt Instrument, Prepayment Fee After Second Anniversary, Percentage						1.00%
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid, Percentage						4.25%
Debt Instrument, Periodic Payment, Increase (Decrease) of Interest-Only Payments											150 days	1 year
Debt Instrument, Periodic Payment, Increase (Decrease) of Periodic Payments											1 year 90 days	1 year 330 days
Debt Instrument, Periodic Payment Terms, Increase (Decrease) in Balloon Payment to be Paid											$ 200,000	$ 100,000		$ 200,000
Oxford Finance, LLC [Member] | Term Loans [Member] | Domain [Member]
Debt Instrument, Periodic Payment Terms, Increase (Decrease) in Balloon Payment to be Paid							$ 50,000
Debt Instrument, Increase of Interest-Only Periodic Payments Upon Delivery of Executed Term Sheet							60 days
Debt Instrument, Increase of Periodic Payments Upon Delivery of Executed Term Sheet							240 days
Proceeds from Noncontrolling Interests							$ 20,000,000
Restricted Cash, Total													$ 200,000
Oxford Finance, LLC [Member] | Term Loans [Member] | Convertible Promissory Note of 1.5 Million [Member]
Debt Instrument, Periodic Payment Terms, Increase (Decrease) in Balloon Payment to be Paid								$ 35,000		$ 25,000					$ 35,000
Debt Instrument, Increase of Interest-Only Periodic Payments Upon Closing of Convertible Note								30 days		30 days
Proceeds from Convertible Debt								$ 1,500,000		$ 1,500,000
Debt Instrument, Increase of Interest-Only Periodic Payments Upon Entering Into a Merger										60 days
Debt Instrument, Increase of Periodic Payments Following Merger										330 days
Debt Instrument, Increase of Periodic Payments Following the Closing of a Convertible Note								300 days
Oxford Finance, LLC [Member] | Term Loans [Member] | London Interbank Offered Rate (LIBOR) Swap Rate [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate						0.19%

Note 5 - Term Loans and Conve_4

Note 5 - Term Loans and Convertible Promissory Notes - Future Principal Payments of Term Loans (Details) $ in Thousands	Dec. 31, 2018USD ($)
Term Loans [Member]
Total principal payments	$ 3,833

Note 5 - Term Loans and Conve_5

Note 5 - Term Loans and Convertible Promissory Notes - Convertible Promissory Notes (Details) - USD ($) $ in Millions	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Convertible note payable	$ 6	$ 4.5
Convertible Note Payable, One [Member]
Convertible note payable	1.5	1.5
Convertible Note Payable Two [Member]
Convertible note payable	1.5	1.5
Convertible Note Payable, Three [Member]
Convertible note payable	1.5	1.5
Convertible Note Payable, Four [Member]
Convertible note payable	$ 1.5

Note 5 - Term Loans and Conve_6

Note 5 - Term Loans and Convertible Promissory Notes - Convertible Promissory Notes (Details) (Parentheticals)	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Convertible Note Payable, One [Member]
Maturity date	Mar. 29, 2019	Mar. 29, 2019
Interest rate	8.00%	8.00%
Convertible Note Payable Two [Member]
Maturity date	Sep. 27, 2019	Sep. 27, 2019
Interest rate	8.00%	8.00%
Convertible Note Payable, Three [Member]
Maturity date	Dec. 21, 2019	Dec. 21, 2019
Interest rate	8.00%	8.00%
Convertible Note Payable, Four [Member]
Maturity date	Mar. 29, 2020
Interest rate	8.00%

Note 6 - Commitments and Cont_3

Note 6 - Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Operating Lease, Expense	$ 67,000	$ 57,000	$ 232,000	$ 225,000

Note 6 - Commitments and Cont_4

Note 6 - Commitments and Contingencies - Future Lease Payments (Details) $ in Thousands	Dec. 31, 2018USD ($)
2019 (remaining 9 months)	$ 180
Total	$ 180

Note 7 - Stockholders' Defici_2

Note 7 - Stockholders' Deficit (Details Textual) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2010
Preferred Stock, Dividends Per Share, Declared	$ 0	$ 0	$ 0	$ 0
Common Stock, Shares Authorized	148,000,000		148,000,000	148,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001		$ 0.001	$ 0.001
Common Stock, Shares, Outstanding, Ending Balance	19,548,969		19,548,969	19,548,969
Common Stock, Dividends, Per Share, Declared			$ 0
Conversion of Preferred Stock to Common Stock [Member]
Equity, Convertible, Aggregate Proceeds Trigger	$ 40
Equity, Convertible, Stock Price Trigger	$ 1
Noncumulative Dividends for Holders of Series B Convertible Preferred Stock [Member]
Dividends Payable, Amount Per Share	0.0251
Noncumulative Dividends for Holders of Series A Convertible Preferred Stock [Member]
Dividends Payable, Amount Per Share	$ 0.0182
Convert Notes and Accrued Interest to Series A Preferred Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued						3,531,889
Convert Notes and Accrued Interest to Series B Preferred Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued					6,469,356
Series A Redeemable Convertible Preferred Stock [Member]
Temporary Equity, Shares Issued	56,672,658		56,672,658	56,672,658
Temporary Equity, Shares Outstanding	56,672,658		56,672,658	56,672,658
Series B Redeemable Convertible Preferred Stock [Member]
Temporary Equity, Shares Issued	51,069,262		51,069,262	51,069,262
Temporary Equity, Remaining Shares Outstanding Requirements To Elect One Director	10,000,000
Temporary Equity, Shares Outstanding	51,069,262		51,069,262	51,069,262
Series B Convertible Preferred Stock [Member]
Temporary Equity, Liquidation Preference Per Share	$ 0.3133
Series A Convertible Preferred Stock [Member]
Temporary Equity, Liquidation Preference Per Share	$ 0.2276

Note 7 - Stockholders' Defici_3

Note 7 - Stockholders' Deficit - Shares Reserved for Future Issuance (Details) - shares shares in Thousands	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Common stock options issued and outstanding (in shares)	19,222	19,222	19,222
Total (in shares)	127,294	127,294	127,294
Warrants Reserve for Series A Convertible Preferred Stock [Member]
Warrants for Series A convertible preferred stock (in shares)	330	330	330
Series A Preferred Stock [Member]
Series A convertible preferred stock (in shares)	56,673	56,673	56,673
Series B Preferred Stock [Member]
Series A convertible preferred stock (in shares)	51,069	51,069	51,069

Note 8 - Warrants (Details Text

Note 8 - Warrants (Details Textual)	Jan. 31, 2016USD ($)$ / sharesyrshares	Nov. 30, 2015USD ($)$ / sharesshares	Jul. 01, 2010$ / shares	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Fair Value Adjustment of Warrants | $				$ 94,000		$ 98,000	$ (12,000)
Warrant to Purchase Series A Convertible Preferred Stock Under Oxford Loan Agreement [Member]
Percentage of Note Payable Principal			20.00%
Class of Warrants or Right, Exercisable, Term	10 years	10 years	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	131,810	197,715
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.2276	$ 0.2276
Warrants Not Settleable in Cash, Fair Value Disclosure | $	$ 22,000	$ 33,000
Warrant to Purchase Series A Convertible Preferred Stock Under Oxford Loan Agreement [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	10	10
Warrant to Purchase Series A Convertible Preferred Stock Under Oxford Loan Agreement [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Warrants and Rights Outstanding, Measurement Input		3.92
Warrant to Purchase Series A Convertible Preferred Stock Under Oxford Loan Agreement [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0209	0.0207
Warrant to Purchase Series A Convertible Preferred Stock Under Oxford Loan Agreement [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	0.686	0.687
Warrant to Purchase Series A Convertible Preferred Stock Under Oxford Loan Agreement [Member] | Measurement Input, Conversion Price [Member]
Warrants and Rights Outstanding, Measurement Input | $ / shares		0.2
Warrant to Purchase Series A Convertible Preferred Stock Under Oxford Loan Agreement [Member] | Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input | $ / shares	0.23
Warrants for Series A Convertible Preferred Stock [Member]
Warrants and Rights Outstanding, Term			7 years
Warrants and Rights Outstanding | $				$ 234,000		$ 140,000	$ 42,000
Warrants for Series A Convertible Preferred Stock [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Warrants and Rights Outstanding, Measurement Input				6.67		6.92	7.92
Warrants for Series A Convertible Preferred Stock [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Warrants and Rights Outstanding, Measurement Input			7	6.83		7.08	8.08
Warrants for Series A Convertible Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input							2.28
Warrants for Series A Convertible Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Warrants and Rights Outstanding, Measurement Input			0.0146	2.27		2.56
Warrants for Series A Convertible Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Warrants and Rights Outstanding, Measurement Input			0.0266	2.28		2.59
Warrants for Series A Convertible Preferred Stock [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input							71
Warrants for Series A Convertible Preferred Stock [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]
Warrants and Rights Outstanding, Measurement Input			0.736	84.44		76.84
Warrants for Series A Convertible Preferred Stock [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]
Warrants and Rights Outstanding, Measurement Input			0.815
Warrants for Series A Convertible Preferred Stock [Member] | Measurement Input, Conversion Price [Member]
Warrants and Rights Outstanding, Measurement Input | $ / shares			0.2276
Warrant Issued In Connection With Term Loan A and B [Member]
Fair Value Adjustment of Warrants | $				$ 95,000		$ 98,000	$ 4,000

Note 8 - Warrants - Details of

Note 8 - Warrants - Details of Warrants (Details)	Mar. 31, 2019$ / sharesshares
Warrants for Series A Convertible Preferred Stock Issued in November, 2015 [Member]
Warrants, exercise price (in dollars per share) | $ / shares	$ 0.2276
Warrants, number of shares outstanding (in shares)	198
Warrants for Series A Convertible Preferred Stock Issued in June, 2016 [Member]
Warrants, exercise price (in dollars per share) | $ / shares	$ 0.2276
Warrants, number of shares outstanding (in shares)	132
Warrants for Series A Convertible Preferred Stock [Member]
Warrants, number of shares outstanding (in shares)	330

Note 8 - Warrants - Warrants As

Note 8 - Warrants - Warrants Assumptions (Details) - Warrants for Series A Convertible Preferred Stock [Member]	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jul. 01, 2010
Measurement Input, Risk Free Interest Rate [Member]
Risk-free interest rate			2.28
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Risk-free interest rate	2.27	2.56		0.0146
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Risk-free interest rate	2.28	2.59		0.0266
Measurement Input, Expected Term [Member] | Minimum [Member]
Risk-free interest rate	6.67	6.92	7.92
Measurement Input, Expected Term [Member] | Maximum [Member]
Risk-free interest rate	6.83	7.08	8.08	7
Measurement Input, Price Volatility [Member]
Risk-free interest rate			71
Measurement Input, Price Volatility [Member] | Minimum [Member]
Risk-free interest rate	84.44	76.84		0.736
Measurement Input, Price Volatility [Member] | Maximum [Member]
Risk-free interest rate				0.815

Note 9 - Stock Option Plans (De

Note 9 - Stock Option Plans (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Common Stock, Capital Shares Reserved for Future Issuance	19,222,000		19,222,000	19,222,000
Share Price			$ 0.46	$ 0.44
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	0		0	0
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount	$ 463,000
Non-employee Stock Options, Comensation Expense, Cost Not yet Recognized, Amount	$ 32,000
Non-employee Stock Options, Comensation Expense, Cost Not yet Recognized, Period for Recognition	180 days
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense	$ 68,000	$ 75,000	$ 293,000	$ 301,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	1 year 273 days
Non-employee Options [Member]
Share-based Payment Arrangement, Expense	$ 16,000	$ 0	$ 16,000	$ 0
The Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance			19,222,032
Share-based Compensation Arrangement by Share-based Payment Award, Options, Minimum Price as Percentage of Estimated Fair Value of Underlying Shares	100.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Minimum Price as Percentage of Estimated Fair Value of Underlying Shares, 10% Shareholder	110.00%
The Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years

Note 9 - Stock Option Plans - S

Note 9 - Stock Option Plans - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Shares Available For Grant, Balance (in shares)		5	5	5
Options Outstanding, Balance (in shares)		19,222	19,222	19,222
Weighted Average Exercise Price Per Share, Balance (in dollars per share)		$ 0.10	$ 0.10	$ 0.10
Weighted-average Remaining Contractual Life, Balance (Year)		7 years 146 days	8 years 146 days	9 years 146 days
Aggregate Intrinsic Value, Balance	[1]	$ 6,956	$ 6,639
Options Outstanding, Vested and expected to vest (in shares)		19,222
Weighted Average Exercise Price Per Share, Vested and expected to vest (in dollars per share)		$ 0.10
Weighted-average Remaining Contractual Life, Vested and expected to vest (Year)		7 years 146 days
Aggregate Intrinsic Value, Vested and expected to vest	[1]	$ 6,956
Options Outstanding, Exercisable (in shares)		11,146
Weighted Average Exercise Price Per Share, Exercisable (in dollars per share)		$ 0.09
Weighted-average Remaining Contractual Life, Exercisable (Year)		7 years 146 days
Aggregate Intrinsic Value, Exercisable	[1]	$ 4,119
[1]	The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the estimated fair value of the Company's common stock of $$0.46 amd $0.44 per share as of December 31, 2018 and 2017.

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual) shares in Thousands	3 Months Ended		12 Months Ended		15 Months Ended
	Mar. 31, 2019USD ($)shares	Mar. 31, 2018USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Mar. 31, 2019USD ($)shares
Income Tax Expense (Benefit), Total	$ 0	$ 0	$ 0	$ 0
Deferred Income Tax Assets, Net, Total	$ 0				$ 0
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount			1,200,000	(964,000)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent					21.00%
Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Total				$ 0
Number of Foreign Subsidiaries | shares	0				0
Operating Loss Carryforwards, Total			33,500,000
Operating Lease Carryforwards with Expiration Dates			28,700,000
Operating Loss Carryforwards Expiring Indefinitely			4,800,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total			0
Domestic Tax Authority [Member]
Open Tax Year	2014 2015 2016 2017 2018
Research Tax Credit Carryforward [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Tax Credit Carryforward, Amount			1,800,000
Research Tax Credit Carryforward [Member] | State and Local Jurisdiction [Member]
Tax Credit Carryforward, Amount			$ 700,000
Earliest Tax Year [Member]
Operating Loss Carryforwards, Expiration Date			Dec. 31, 2033
Earliest Tax Year [Member] | Research Tax Credit Carryforward [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Tax Credit Carryforward, Expiration Date			Dec. 31, 2031

Note 10 - Income Taxes - Compon

Note 10 - Income Taxes - Components of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Net operating loss carry forward	$ 7,051	$ 6,158
Research and development credits	1,601	1,284
Accruals and reserves	142	99
Fixed assets	1
Total deferred tax asset	8,795	7,541
Valuation allowance	(8,795)	(7,541)
Net deferred tax asset

Note 10 - Income Taxes - Activi

Note 10 - Income Taxes - Activity Related to Gross Unrecognized Tax Benefits (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)
Balance	$ 331
Changes related to prior year positions	330
Increases related to current year positions	42
Balance	$ 703

Note 11 - Related-party Trans_2

Note 11 - Related-party Transactions (Details Textual) - USD ($)	May 03, 2019	May 30, 2019	Apr. 30, 2019	Mar. 31, 2019
Subsequent Event [Member] | Conversion of Notes into Series B Convertible Preferred Stock [Member]
Debt Conversion, Original Debt, Amount, Principal	$ 3,000,000
Debt Conversion, Original Debt, Amount, Cumulative Accrued Interest	$ 203,000
Subsequent Event [Member] | Conversion of Notes into Series B Convertible Preferred Stock [Member] | Series B Convertible Preferred Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued	10,223,996
Majority Investors [Member]
Debt Instrument, Face Amount				$ 6,000,000
Debt Instrument, Interest Rate, Stated Percentage				8.00%
Interest Payable				$ 215,000
Majority Investors [Member] | Subsequent Event [Member]
Proceeds from Notes Payable, Total		$ 500,000	$ 2,000,000

Note 12 - Employee Benefit Pl_2

Note 12 - Employee Benefit Plan (Details Textual) - USD ($)	12 Months Ended		24 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018
Defined Contribution Plan, Non-elective Safe Harbor Contribution, Percentage of Annual Salary			3.00%
Defined Contribution Plan, Non-elective Safe Harbor Contribution, Amount	$ 49,000	$ 54,000

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) - USD ($)	May 31, 2019	May 03, 2019	Apr. 30, 2019	May 31, 2019	May 30, 2019	Apr. 30, 2019	Mar. 31, 2019
Majority Investors [Member]
Debt Instrument, Interest Rate, Stated Percentage							8.00%
Subsequent Event [Member]
Merger Agreement, Percentage Ownership in Combined Company, Acquirer		86.00%
Merger Agreement, Percentage Ownership in Combined Company, Acquiree		14.00%
Subsequent Event [Member] | Conversion of Notes into Series B Convertible Preferred Stock [Member]
Debt Conversion, Original Debt, Amount, Principal		$ 3,000,000
Debt Conversion, Original Debt, Amount, Cumulative Accrued Interest		$ 203,000
Subsequent Event [Member] | Conversion of Notes into Series B Convertible Preferred Stock [Member] | Series B Convertible Preferred Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued		10,223,996
Subsequent Event [Member] | Majority Investors [Member]
Proceeds from Notes Payable, Total					$ 500,000	$ 2,000,000
Subsequent Event [Member] | Majority Investors [Member] | First Note to Fund the Company's Operations [Member]
Proceeds from Notes Payable, Total			$ 2,000,000			$ 2,000,000
Debt Instrument, Maturity Date						Apr. 26, 2020
Subsequent Event [Member] | Majority Investors [Member] | Second Note to Fund the Company's Operations [Member]
Proceeds from Notes Payable, Total	$ 500,000			$ 500,000
Debt Instrument, Maturity Date				May 29, 2020
Subsequent Event [Member] | Majority Investors [Member] | Notes to Fund the Company's Operations [Member]
Debt Instrument, Interest Rate, Stated Percentage	8.00%			8.00%